|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,610,612: Gene Editing Technology
This report provides a critical analysis of United States Patent 10,610,612, focusing on its claims, the underlying technology, and the competitive patent landscape. The patent, titled "CRISPR-CAS9 GENE EDITING METHOD AND MODIFIED TARGET GENE," describes a method for targeting and modifying specific DNA sequences using the CRISPR-Cas9 system. Its claims are broad and cover fundamental aspects of CRISPR-Cas9 gene editing, including the use of a guide RNA (gRNA) to direct the Cas9 nuclease to a target DNA sequence for modification. The patent's issuance has significant implications for research, development, and commercialization of gene editing technologies.
What are the core claims of US Patent 10,610,612?
US Patent 10,610,612, granted on April 7, 2020, to the Broad Institute of MIT and Harvard, encompasses claims related to the foundational use of the CRISPR-Cas9 system for gene editing. The patent's strength lies in its broad interpretation of how the CRISPR-Cas9 system can be applied in various cellular contexts.
-
Claim 1: This is a foundational independent claim. It describes a method for modifying a target polynucleotide in a eukaryotic cell. The method involves:
- Introducing into the cell a Cas9 protein (or a functional equivalent) and a guide RNA (gRNA).
- The gRNA is designed to be complementary to a target sequence within the target polynucleotide.
- The Cas9 protein, directed by the gRNA, creates a double-strand break in the target polynucleotide at a specific location within or near the target sequence.
- The modification of the target polynucleotide occurs at the site of the double-strand break. This modification can be deletion, insertion, or substitution of nucleotides.
-
Dependent Claims: Numerous dependent claims further refine and broaden the scope of the invention. These include variations in:
- The specific type of Cas9 protein or its modified forms.
- The design and composition of the gRNA, including single-molecule gRNAs (smRNAs) and chemically modified gRNAs.
- The method of delivering the Cas9 protein and gRNA into the cell (e.g., using viral vectors, lipid nanoparticles, or electroporation).
- The specific types of eukaryotic cells in which the method can be applied (e.g., mammalian cells, plant cells).
- The application of the method for specific purposes, such as gene knockout, gene insertion, or gene correction.
The claims differentiate themselves by focusing on the delivery of both the Cas9 nuclease and the guide RNA into a eukaryotic cell and the subsequent targeted DNA modification. This contrasts with some other foundational CRISPR patents that may focus solely on prokaryotic applications or specific components.
How does US Patent 10,610,612 define the CRISPR-Cas9 system?
The patent defines the CRISPR-Cas9 system through its functional components and their interactions to achieve targeted DNA cleavage and modification.
-
Cas9 Protein: The patent covers the use of a Cas9 nuclease or a functional equivalent. This includes both naturally occurring Cas9 proteins (e.g., from Streptococcus pyogenes) and engineered variants that retain the nuclease activity necessary for creating DNA breaks. The patent generally refers to Cas9 as a protein that recognizes a target sequence with the aid of a guide RNA and cleaves the DNA.
-
Guide RNA (gRNA): The patent is particularly focused on the role of the gRNA in directing the Cas9 nuclease. The gRNA is described as a nucleic acid molecule that contains a sequence complementary to the target DNA sequence. This complementary sequence, often referred to as the "spacer" or "guide" sequence, binds to the target DNA. The gRNA also contains a scaffold region that binds to the Cas9 protein, forming an active ribonucleoprotein complex. The patent acknowledges various forms of gRNA, including those that combine the functions of CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA) into a single molecule (smRNA).
-
Mechanism of Action: The patent's core mechanism involves the assembly of a Cas9-gRNA ribonucleoprotein complex. Upon introduction into a cell, this complex searches the genome for a DNA sequence complementary to the gRNA's guide sequence. Binding to the target sequence, typically in conjunction with a protospacer adjacent motif (PAM) sequence, positions the Cas9 nuclease to create a double-strand break at a precise location. The cell's natural DNA repair mechanisms then act upon this break, leading to the desired gene modification (e.g., disruption, insertion, or replacement).
The patent's definition is broad enough to encompass various iterations of the CRISPR-Cas9 system that utilize these core components for gene editing in eukaryotic cells.
What is the technological scope of the patented method?
The technological scope of US Patent 10,610,612 is extensive, covering the fundamental application of CRISPR-Cas9 for gene editing across a wide range of biological systems and research applications.
-
Target Modification Types: The patent covers various types of DNA modifications resulting from the double-strand break induced by the Cas9-gRNA complex. These include:
- Gene Disruption/Knockout: Introduction of insertions or deletions (indels) that disrupt the reading frame of a gene, rendering it non-functional.
- Gene Insertion/Correction: Utilizing homologous recombination pathways to insert new DNA sequences or correct existing mutations at the site of the double-strand break.
- Sequence Alteration: Direct nucleotide substitutions or larger sequence replacements.
-
Cellular Context: The patent explicitly claims methods applicable to eukaryotic cells. This is a critical aspect, as eukaryotic cells are the basis for all human, animal, and plant research and therapeutic development. This broad scope distinguishes it from patents focused solely on prokaryotic systems.
-
Delivery Methods: While not claiming specific delivery methods as the core invention, the patent encompasses scenarios where the Cas9 protein and gRNA are introduced into the cell through various means. This includes but is not limited to:
- Viral vectors (e.g., lentiviruses, adenoviruses).
- Non-viral delivery methods such as lipid nanoparticles, electroporation, and direct injection of ribonucleoprotein complexes.
-
Applications: The broad claims suggest applicability in a multitude of research and potential therapeutic areas, including:
- Basic Research: Understanding gene function, creating disease models, and studying cellular pathways.
- Drug Discovery and Development: Screening targets, validating drug candidates.
- Gene Therapy: Correcting genetic defects underlying inherited diseases.
- Agricultural Biotechnology: Developing genetically modified crops with enhanced traits.
The patent's broad claims are a significant factor in its commercial and legal significance, as they encompass a wide array of downstream applications and variations of the CRISPR-Cas9 technology.
What is the competitive patent landscape for CRISPR-Cas9 technology?
The CRISPR-Cas9 patent landscape is complex and highly contested, with multiple entities holding key patents covering different aspects of the technology. US Patent 10,610,612 is a central piece in this landscape, but it is not the sole foundational patent.
-
Key Players:
- Broad Institute of MIT and Harvard: Holds US Patent 10,610,612 and other related patents covering the application of CRISPR-Cas9 in eukaryotic cells.
- University of California (UC) System: Holds foundational patents (e.g., US Patent 8,697,359) that broadly cover the CRISPR-Cas9 system, including its use in prokaryotes and eukaryotes, focusing on specific Cas proteins and guide RNA structures.
- Emmanuelle Charpentier and Jennifer Doudna (and their institutions): Hold foundational patents related to the CRISPR-Cas9 system, particularly the dual-RNA system (crRNA and tracrRNA) and its use in gene editing. These patents are licensed to various companies.
- Other Institutions and Companies: Numerous other patents exist covering specific CRISPR systems (e.g., Cas12, Cas13), delivery methods, engineered nucleases, and specific therapeutic applications.
-
Key Disputes and Litigation:
- Broad Institute vs. UC System: This has been a prominent dispute concerning inventorship and the scope of foundational CRISPR patents. The core of the dispute often revolved around whether the UC patents covered the application of CRISPR-Cas9 in eukaryotic cells, as claimed by the Broad Institute. Interferences and litigation have been ongoing.
- Licensing and Cross-Licensing: Companies developing CRISPR-based therapies are actively seeking licenses from the primary patent holders. Extensive licensing agreements and cross-licensing deals are in place, creating a complex web of intellectual property rights.
-
Patent Expiration: Many of the earliest foundational CRISPR patents are nearing or have already expired. However, newer patents covering specific applications, delivery systems, and next-generation CRISPR technologies continue to be filed and granted.
The landscape is dynamic, with ongoing legal challenges, new patent filings, and evolving licensing strategies shaping the commercialization pathways for CRISPR technologies.
What are the potential implications of US Patent 10,610,612 for R&D and investment?
US Patent 10,610,612, by virtue of its broad claims covering the application of CRISPR-Cas9 in eukaryotic cells, has significant implications for research and development efforts, as well as investment decisions in the biotechnology sector.
-
Research & Development:
- Freedom to Operate: Researchers and institutions must carefully assess their freedom to operate concerning the claims of this patent. Activities that fall directly within the scope of the patent may require licensing.
- Strategic Development: The patent encourages the development of CRISPR applications that either operate outside its core claims or are covered by licenses. This might involve focusing on different CRISPR effectors (e.g., Cas12, Cas13), novel delivery methods, or gene editing techniques that do not rely on double-strand breaks.
- Innovation Driver: The existence of broad patents can sometimes stimulate innovation in areas not covered, leading to diversification of gene editing technologies.
-
Investment:
- Licensing Costs: Companies developing CRISPR-based therapeutics or diagnostic tools will likely incur licensing fees for using the technology claimed in this patent. These costs can be substantial and impact the economic viability of R&D projects.
- Valuation of CRISPR Companies: The licensing status and the scope of foundational patents like US Patent 10,610,612 are critical factors in the valuation of companies operating in the CRISPR space. Companies with robust IP portfolios or favorable licensing agreements are generally more attractive investments.
- Risk Assessment: Investors must evaluate the patent landscape and potential litigation risks associated with specific CRISPR technologies. Disputes between major patent holders can create uncertainty and impact stock prices.
- Emerging Technologies: Investment is increasingly directed towards next-generation gene editing technologies that may circumvent existing patents or offer distinct advantages, such as base editing and prime editing.
The patent's broad claims necessitate careful intellectual property strategy for any entity seeking to develop or commercialize CRISPR-based products.
What is the potential market impact of the CRISPR-Cas9 technology covered by this patent?
The CRISPR-Cas9 technology, as broadly encompassed by patents like US Patent 10,610,612, is poised to have a transformative impact across multiple markets.
The market impact is contingent on regulatory approvals, clinical trial success, and the ability of companies to navigate the complex intellectual property landscape. However, the foundational nature of the technology suggests a substantial and enduring influence across these sectors.
Key Takeaways
US Patent 10,610,612 represents a significant foundational patent for CRISPR-Cas9 gene editing in eukaryotic cells. Its broad claims cover the core method of using Cas9 protein and guide RNA to induce targeted DNA modifications. The competitive patent landscape is intricate, involving multiple key institutions and ongoing disputes that influence licensing and commercialization strategies. The technology's potential market impact spans therapeutics, diagnostics, agriculture, and research tools, making careful IP analysis crucial for R&D and investment decisions.
FAQs
-
Does US Patent 10,610,612 cover all CRISPR gene editing methods?
No, it primarily covers methods using the Cas9 nuclease in eukaryotic cells. Other CRISPR-associated enzymes (e.g., Cas12) and systems, as well as methods specifically in prokaryotic cells or non-nuclease applications of CRISPR components, may be covered by different patents.
-
Are the technologies claimed by US Patent 10,610,612 still under patent protection?
The patent was granted in 2020 and has a term of 20 years from the filing date. Therefore, the core claims are still protected, although the exact expiration date depends on the original filing date and any applicable patent term extensions.
-
What are the main differences between US Patent 10,610,612 and other foundational CRISPR patents?
A key distinction often lies in the scope of application. US Patent 10,610,612 is recognized for its strong claims related to the application of CRISPR-Cas9 in eukaryotic cells, which is critical for human therapeutics and biotechnology. Other foundational patents might focus on the fundamental discovery of the CRISPR system, its components in prokaryotes, or specific RNA structures.
-
How does the patent landscape affect companies developing CRISPR therapies?
Companies must secure licenses from the relevant patent holders to avoid infringement. This can involve significant licensing fees and royalties, impacting development costs and profitability. The ongoing patent disputes also create uncertainty.
-
What are the alternatives for researchers who cannot license the technology covered by US Patent 10,610,612?
Alternatives include developing or using technologies not covered by the patent's claims, such as different gene editing systems (e.g., base editors, prime editors, zinc-finger nucleases, TALENs), novel delivery methods, or focusing on applications that might fall outside the patent's explicit scope. Collaborations or licensing from other patent holders are also options.
Citations
[1] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829
[2] Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823. https://doi.org/10.1126/science.1231143
[3] Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823–826. https://doi.org/10.1126/science.1232033
[4] United States Patent 10,610,612. (2020). CRISPR-CAS9 GENE EDITING METHOD AND MODIFIED TARGET GENE. Assignee: Broad Institute of MIT and Harvard.
[5] Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096
More… ↓
⤷ Start Trial
|
